GLP-1 agonists: Effects on plasma lipid profile?
Professor Gary LewisWatch the presentation >
Should we be lowering TG levels in the range between 150 and 500 mg/dL, and if so, how? Setting the scene
Professor Gerald F WattsWatch the presentation >
ANGPTL4 inhibition: Phase 2a and ongoing trials
Nicholas MarstonWatch the presentation >
ANGPTL4: New insights into an “old” lipid regulatory protein
Dr Sander KerstenWatch the presentation >
Per particle atherogenicity: Remnants vs LDL vs Lp(a)
Dr Elias BjörnsonWatch the presentation >
Remnant lipoproteins: What do we know?
Professor M. John Chapman (Co-Chair)Watch the presentation >
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
